Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zalcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.57 |
| ▸ | ALB | P02768 | 3/20 | 0.57 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.57 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.57 |
| ▸ | POLG | P54098 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zalcitabine SCHEMBL285163 | 1.00 | ABL1 (0.57) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL6913582 | 0.95 | ABL1 (0.55) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL12149465 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL598496 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL3715526 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL21100417 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL3235525 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL3598 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL8094882 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL9194365 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025042729-A1 | CELL PREPARATION COMPOSITION, SYSTEM AND METHOD FOR SINGLE CELL TRANSCRIPTOMICS | Life Technologies Corporation (US) | 2025-02-27 | — | — | WO | claimed |
| EP-4479406-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | Promega Corporation (US) | 2024-12-25 | — | — | EP | claimed |
| US-20240287502-A1 | OLIGONUCLEOTIDE-TETHERED NUCLEOTIDES | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2024-08-29 | — | — | US | claimed |
| US-20240102003-A1 | OLIGONUCLEOTIDE-TETHERED NUCLEOTIDES | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2024-03-28 | — | — | US | claimed |
| US-20230278968-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | PROMEGA CORPORATION | 2023-09-07 | — | — | US | claimed |
| WO-2023159042-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | PROMEGA CORPORATION (US) | 2023-08-24 | — | — | WO | claimed |
| US-11485997-B2 | Nucleic acid sequence identification using solid-phase cyclic single base extension | INSILIXA, INC. (US) | 2022-11-01 | — | — | US | claimed |
| CN-114450401-A | Oligonucleotide-tethered nucleotide triphosphates useful for labeling nucleic acids for making next generation sequencing libraries | 赛默飞世尔科技波罗的海封闭股份公司 | 2022-05-06 | — | — | CN | claimed |
| EP-3986907-A1 | OLIGONUCLEOTIDE-TETHERED TRIPHOSPHATE NUCLEOTIDES USEFUL FOR LABELLING NUCLEIC ACIDS FOR PREPARING NEXT-GENERATION SEQUENCING LIBRARIES | Thermo Fisher Scientific Baltics UAB (LT) | 2022-04-27 | — | — | EP | claimed |
| US-20200399633-A1 | OLIGONUCLEOTIDE-TETHERED NUCLEOTIDES | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2020-12-24 | — | — | US | claimed |
| WO-1994016101-A2 | DNA SEQUENCING BY MASS SPECTROMETRY | KOESTER HUBERT (US) | 1994-07-21 | — | — | WO | claimed |
| EP-0496749-A4 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION | — | 1993-06-16 | — | — | EP | claimed |
| EP-0496749-A1 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION. | APPLIED BIOSYSTEMS (US) | 1992-08-05 | — | — | EP | claimed |
| EP-0286418-B1 | ANTI-RETROVIRAL AGENTS AND DELIVERY SYSTEMS FOR THE SAME | US COMMERCE (US) | 1992-07-08 | — | — | EP | claimed |
| EP-0416011-A4 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | US COMMERCE (US) | 1991-05-22 | — | — | EP | claimed |
| WO-1991005060-A2 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION | APPLIED BIOSYSTEMS, INC. (US) | 1991-04-18 | — | — | WO | claimed |
| EP-0416011-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1991-03-13 | — | — | EP | claimed |
| WO-1989011274-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-11-30 | — | — | WO | claimed |
| US-4879277-A | 2',3'-DIDEOXYCYTIDINE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1989-11-07 | — | — | US | claimed |
| EP-0298280-A2 | Animal derived cell with antigenic protein introduced therein | HAPGOOD, C.V., a Netherlands Antilles Limited Partnership (US) | 1989-01-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278968-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | POLRMT, POLB, POLN | ABL1 1875/4885RIN1 4788/4885LMNA 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.